193 related articles for article (PubMed ID: 31704974)
1. Mutation of the PTCH1 gene predicts recurrence of breast cancer.
Wang CY; Chang YC; Kuo YL; Lee KT; Chen PS; Cheung CHA; Chang CP; Phan NN; Shen MR; Hsu HP
Sci Rep; 2019 Nov; 9(1):16359. PubMed ID: 31704974
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
[TBL] [Abstract][Full Text] [Related]
3. SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.
Hassan N; Rutsch N; Győrffy B; Espinoza-Sánchez NA; Götte M
Sci Rep; 2020 Feb; 10(1):2262. PubMed ID: 32042016
[TBL] [Abstract][Full Text] [Related]
4. Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Edenfield J; Schammel C; Collins J; Schammel D; Edenfield WJ
Clin Breast Cancer; 2017 Feb; 17(1):e1-e10. PubMed ID: 27568101
[TBL] [Abstract][Full Text] [Related]
5. Predictive of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer.
Lu K; Li H; Wu Z; Liu D; Ye H; Xu L; Liu Y
J BUON; 2018; 23(5):1297-1301. PubMed ID: 30570850
[TBL] [Abstract][Full Text] [Related]
6. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
7. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer.
Kim S; Rimm D; Carter D; Khan A; Parisot N; Franco MA; Bale A; Haffty BG
Breast J; 2003; 9(3):167-74. PubMed ID: 12752624
[TBL] [Abstract][Full Text] [Related]
8. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
9. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
10. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
11. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
12. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
13. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
[TBL] [Abstract][Full Text] [Related]
14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
15. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Hortobagyi GN; Chen D; Piccart M; Rugo HS; Burris HA; Pritchard KI; Campone M; Noguchi S; Perez AT; Deleu I; Shtivelband M; Masuda N; Dakhil S; Anderson I; Robinson DM; He W; Garg A; McDonald ER; Bitter H; Huang A; Taran T; Bachelot T; Lebrun F; Lebwohl D; Baselga J
J Clin Oncol; 2016 Feb; 34(5):419-26. PubMed ID: 26503204
[TBL] [Abstract][Full Text] [Related]
16. Hepatosteatosis may predict late recurrence of breast cancer: A single-center observational study.
Kus T; Cinkir HY; Aktas G; Abali H
Curr Probl Cancer; 2019 Dec; 43(6):100461. PubMed ID: 30686567
[TBL] [Abstract][Full Text] [Related]
17. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
19. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
Craig DW; O'Shaughnessy JA; Kiefer JA; Aldrich J; Sinari S; Moses TM; Wong S; Dinh J; Christoforides A; Blum JL; Aitelli CL; Osborne CR; Izatt T; Kurdoglu A; Baker A; Koeman J; Barbacioru C; Sakarya O; De La Vega FM; Siddiqui A; Hoang L; Billings PR; Salhia B; Tolcher AW; Trent JM; Mousses S; Von Hoff D; Carpten JD
Mol Cancer Ther; 2013 Jan; 12(1):104-16. PubMed ID: 23171949
[TBL] [Abstract][Full Text] [Related]
20. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.
Sinha S; Singh RK; Alam N; Roy A; Roychoudhury S; Panda CK
Mol Cancer; 2008 Nov; 7():84. PubMed ID: 18990233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
